GlaxoSmithKline Pharmaceuticals (GLAXO.BO) Earnings Analysis
GlaxoSmithKline Pharmaceuticals (GLAXO.BO) next reports earnings on 2026-08-03, consensus EPS 13.9 INR. Last quarter (2026-05-14) it beat with EPS 16.4 INR vs 16.4 INR est (0%). It has beaten estimates in 2/2 recent quarters (100%). Trailing P/E 40.85.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GLAXO.BO next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | 13.9 INR |
| Revenue estimate | 10.14B |
GLAXO.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | 16.4 INR | 16.4 INR | 0% | Beat |
| 2026-02-09 | 16.7 INR | 16.7 INR | 0% | Beat |
| 2025-10-27 | 15 INR | n/a | n/a | n/a |
| 2025-08-01 | 12.1 INR | n/a | n/a | n/a |
| 2025-02-14 | 12.8 INR | n/a | n/a | n/a |
| 2024-08-02 | 10.9 INR | n/a | n/a | n/a |
Beat rate: 2/2 (100%) over reported quarters with consensus data.
GLAXO.BO valuation and analyst view
| Trailing P/E | 40.85 |
|---|---|
| Trailing EPS | 61.146 INR |
| Price / book | 18.67 |
| Dividend yield | 2.28% |
| Market cap | 432.40B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is GlaxoSmithKline Pharmaceuticals (GLAXO.BO)'s next earnings date?
GlaxoSmithKline Pharmaceuticals is next scheduled to report on 2026-08-03, with a consensus EPS estimate of 13.9 INR and revenue estimate of 10.14B.
Did GLAXO.BO beat earnings last quarter?
In its 2026-05-14 report, GLAXO.BO posted EPS of 16.4 INR versus a 16.4 INR estimate — a beat of 0%.
What is GLAXO.BO's earnings track record?
Over the last 2 reported quarters with consensus data, GLAXO.BO beat estimates 2 times (100%).
What is GLAXO.BO's current P/E ratio and EPS?
GLAXO.BO trades at a trailing P/E of 40.85 on trailing EPS of 61.14609831963028 INR.
What do analysts rate GLAXO.BO?
GLAXO.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.